Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 4:27 PM
Ignite Modification Date:
2025-12-25 @ 2:20 PM
NCT ID:
NCT05113966
Group ID:
EG000
Title:
Trilaciclib + Sacituzumab Govitecan-hziy
Description:
Participants received trilaciclib + sacituzumab govitecan-hziy on Days 1 and 8 of a 21-day cycle. Trilaciclib was administered first, followed by sacituzumab govitecan-hziy. Administer diluted trilaciclib solution as a 30-minute IV infusion completed within 4 hours prior to the start of sacituzumab govitecan-hziy.
Trilaciclib: Single-use, sterile powder reconstituted and further diluted with 250 mL of normal saline (sodium chloride solution 0.9%) or D5W Sacituzumab Govitecan-hziy: 10 mg/kg reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
Deaths Number Affected:
21
Deaths Number At Risk:
None
Serious Number Affected:
6
Serious Number At Risk:
30
Other Number Affected:
29
Other Number At Risk:
30
Study:
NCT05113966
Results Section:
NCT05113966
Adverse Events Module:
NCT05113966